| P50 | author | Felipe Prosper | Q37835050 |
| | Michaela R. Reagan | Q38328074 |
| | Antonio Sacco | Q40001595 |
| | Aldo M Roccaro | Q40001639 |
| | Matteo Bellone | Q47407154 |
| | Arianna Calcinotto | Q58882639 |
| | Yawara Kawano | Q84529928 |
| P2093 | author name string | A Vacca | |
| | J Shi | |
| | M Chesi | |
| | M Moschetta | |
| | Y Mishima | |
| | I Sahin | |
| | B Paiva | |
| | C Unitt | |
| | I M Ghobrial | |
| | L P Bergsagel | |
| | L Palomera | |
| | S Glavey | |
| | S Manier | |
| | Y Aljawai | |
| P2860 | cites work | The definition of EPCs and other bone marrow cells contributing to neoangiogenesis and tumor growth: is there common ground for understanding the roles of numerous marrow-derived cells in the neoangiogenic process? | Q37374031 |
| | Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back | Q37466938 |
| | Role of endothelial progenitor cells in cancer progression | Q38202716 |
| | Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. | Q39347815 |
| | Circulating endothelial progenitor cells, vascular function, and cardiovascular risk | Q39513285 |
| | Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. | Q40412896 |
| | Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma | Q41591687 |
| | AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. | Q43059808 |
| | Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma | Q43242194 |
| | Circulating endothelial progenitor cells in multiple myeloma: implications and significance | Q45200875 |
| | Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells | Q46882677 |
| | Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis | Q50669459 |
| | Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma | Q54614177 |
| | Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial | Q56645266 |
| | Angiogenesis in hematologic malignancies | Q73119139 |
| | Prognostic value of bone marrow angiogenesis in multiple myeloma | Q74216118 |
| | Bone marrow angiogenesis and progression in multiple myeloma | Q83699933 |
| | Molecular Mechanisms of Tumor Angiogenesis | Q84736698 |
| | Establishment of outgrowth endothelial cells from peripheral blood | Q84862145 |
| | Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma | Q85045006 |
| | C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma | Q87635685 |
| | Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum | Q24594356 |
| | Origins of circulating endothelial cells and endothelial outgrowth from blood | Q24599869 |
| | Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma | Q24647620 |
| | Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts | Q28146071 |
| | Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth | Q28203327 |
| | Circulating endothelial progenitor cells and cardiovascular outcomes | Q28271167 |
| | Molecular mechanisms and clinical applications of angiogenesis | Q29547314 |
| | Id1 restrains p21 expression to control endothelial progenitor cell formation | Q33311286 |
| | CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma | Q34209313 |
| | Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy | Q34263870 |
| | Bone marrow angiogenesis and progression in multiple myeloma. | Q34292940 |
| | Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators | Q34294698 |
| | Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals | Q34575418 |
| | Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach | Q35175287 |
| | Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial | Q35736586 |
| | Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization | Q36494552 |
| | Angiogenesis and antiangiogenic therapy in hematologic malignancies. | Q36692235 |
| | BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. | Q36733492 |
| | Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. | Q36831312 |
| | Mouse models of human myeloma | Q36998207 |
| | Antiangiogenesis in haematological malignancies. | Q37335525 |
| P433 | issue | 5 | |
| P921 | main subject | vasculogenesis | Q1424593 |
| P304 | page(s) | 1103-1115 | |
| P577 | publication date | 2016-02-03 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Targeting vasculogenesis to prevent progression in multiple myeloma | |
| P478 | volume | 30 | |